Recent from talks
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to Ramosetron.
Nothing was collected or created yet.
Ramosetron
View on Wikipediafrom Wikipedia
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth (ODT), IV |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 5.8 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H17N3O |
| Molar mass | 279.343 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".[2] In India it is marketed under the brand name of Ibset.
It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5]
References
[edit]- ^ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
- ^ "2008 News Releases - Astellas Pharma Inc". www.astellas.com.
- ^ Summary in Japanese. Retrieved on September 4, 2012.
- ^ "2013 News Releases | Astellas Pharma Inc". www.astellas.com. Retrieved 2018-04-06.
- ^ Abridged prescribing information — Nasea (MIMS Philippines)[permanent dead link]. Retrieved on June 13, 2008.